FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894922801> ?p ?o ?g. }

• W2894922801 abstract "Acute severe haemorrhage is a common complication of injury, childbirth, surgery, gastrointestinal pathologies and other medical conditions. Bleeding is a major cause of death, but patients also die from non-bleeding causes, the frequency of which varies by the site of haemorrhage and between populations. Because patients can bleed to death within hours, established interventions inevitably take priority over randomisation into a trial. These circumstances raise challenges in selecting appropriate outcome measures for clinical trials of haemostatic interventions. We use data from three large randomised controlled trials in acute severe haemorrhage (CRASH-2, WOMAN and HALT-IT) to explore the strengths and limitations of outcome measures commonly used in trials of haemostatic treatments, including all-cause and cause-specific mortality, blood transfusion and surgical interventions. Many deaths following acute severe haemorrhage are due to patient comorbidities or complications rather than bleeding. If non-bleeding deaths are unaffected by a haemostatic intervention, even large trials will have low power to detect an effect on all-cause mortality. Due to the dilution from deaths unaffected or reduced by the trial treatment, all-cause mortality can also obscure important harmful effects. Additionally, because the relative contributions of different causes of death vary within and between patient populations, all-cause mortality is not generalisable. Different causes of death occur at different time intervals from bleeding onset, with bleeding deaths generally occurring early. Time-specific mortality can therefore be used as a proxy for cause in un-blinded trials where bias is a concern or in situations where cause of death cannot be assessed. Urgent treatment is critical, and so post-randomisation blood transfusion and surgery are often planned before or at the time of randomisation and therefore cannot be influenced by the trial treatment. All-cause mortality has low power, lacks generalisability and can obscure harmful effects. Cause-specific mortality, such as death due to bleeding or thrombosis, avoids these drawbacks. In certain scenarios, time-specific mortality can be used as a proxy for cause-specific mortality. Blood transfusion and surgical procedures have limited utility as outcome measures in trials of haemostatic treatments." @default.
• W2894922801 created "2018-10-12" @default.
• W2894922801 creator A5009907000 @default.
• W2894922801 creator A5018342534 @default.
• W2894922801 creator A5022237789 @default.
• W2894922801 creator A5024174544 @default.
• W2894922801 creator A5030861804 @default.
• W2894922801 creator A5034135548 @default.
• W2894922801 creator A5040169514 @default.
• W2894922801 creator A5082884598 @default.
• W2894922801 date "2018-10-01" @default.
• W2894922801 modified "2023-10-12" @default.
• W2894922801 title "Outcome measures in clinical trials of treatments for acute severe haemorrhage" @default.
• W2894922801 cites W1522407287 @default.
• W2894922801 cites W1549647476 @default.
• W2894922801 cites W1562820142 @default.
• W2894922801 cites W1897623101 @default.
• W2894922801 cites W1939149497 @default.
• W2894922801 cites W1977884651 @default.
• W2894922801 cites W1993118867 @default.
• W2894922801 cites W2025184903 @default.
• W2894922801 cites W2038630181 @default.
• W2894922801 cites W2039415880 @default.
• W2894922801 cites W2070507194 @default.
• W2894922801 cites W2087268973 @default.
• W2894922801 cites W2094352150 @default.
• W2894922801 cites W2098067731 @default.
• W2894922801 cites W2107339086 @default.
• W2894922801 cites W2125149930 @default.
• W2894922801 cites W2132647449 @default.
• W2894922801 cites W2146514939 @default.
• W2894922801 cites W2149533973 @default.
• W2894922801 cites W2150384583 @default.
• W2894922801 cites W2162249417 @default.
• W2894922801 cites W2253155352 @default.
• W2894922801 cites W2257866789 @default.
• W2894922801 cites W2546046192 @default.
• W2894922801 cites W2607870311 @default.
• W2894922801 cites W2767208517 @default.
• W2894922801 cites W2804714053 @default.
• W2894922801 cites W2809099124 @default.
• W2894922801 cites W4210987237 @default.
• W2894922801 doi "https://doi.org/10.1186/s13063-018-2900-4" @default.
• W2894922801 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6167881" @default.
• W2894922801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30285839" @default.
• W2894922801 hasPublicationYear "2018" @default.
• W2894922801 type Work @default.
• W2894922801 sameAs 2894922801 @default.
• W2894922801 citedByCount "26" @default.
• W2894922801 countsByYear W28949228012018 @default.
• W2894922801 countsByYear W28949228012019 @default.
• W2894922801 countsByYear W28949228012020 @default.
• W2894922801 countsByYear W28949228012021 @default.
• W2894922801 countsByYear W28949228012022 @default.
• W2894922801 countsByYear W28949228012023 @default.
• W2894922801 crossrefType "journal-article" @default.
• W2894922801 hasAuthorship W2894922801A5009907000 @default.
• W2894922801 hasAuthorship W2894922801A5018342534 @default.
• W2894922801 hasAuthorship W2894922801A5022237789 @default.
• W2894922801 hasAuthorship W2894922801A5024174544 @default.
• W2894922801 hasAuthorship W2894922801A5030861804 @default.
• W2894922801 hasAuthorship W2894922801A5034135548 @default.
• W2894922801 hasAuthorship W2894922801A5040169514 @default.
• W2894922801 hasAuthorship W2894922801A5082884598 @default.
• W2894922801 hasBestOaLocation W28949228011 @default.
• W2894922801 hasConcept C118552586 @default.
• W2894922801 hasConcept C126322002 @default.
• W2894922801 hasConcept C141071460 @default.
• W2894922801 hasConcept C168563851 @default.
• W2894922801 hasConcept C177713679 @default.
• W2894922801 hasConcept C194828623 @default.
• W2894922801 hasConcept C27415008 @default.
• W2894922801 hasConcept C2776259030 @default.
• W2894922801 hasConcept C2779134260 @default.
• W2894922801 hasConcept C29374701 @default.
• W2894922801 hasConcept C535046627 @default.
• W2894922801 hasConcept C71924100 @default.
• W2894922801 hasConceptScore W2894922801C118552586 @default.
• W2894922801 hasConceptScore W2894922801C126322002 @default.
• W2894922801 hasConceptScore W2894922801C141071460 @default.
• W2894922801 hasConceptScore W2894922801C168563851 @default.
• W2894922801 hasConceptScore W2894922801C177713679 @default.
• W2894922801 hasConceptScore W2894922801C194828623 @default.
• W2894922801 hasConceptScore W2894922801C27415008 @default.
• W2894922801 hasConceptScore W2894922801C2776259030 @default.
• W2894922801 hasConceptScore W2894922801C2779134260 @default.
• W2894922801 hasConceptScore W2894922801C29374701 @default.
• W2894922801 hasConceptScore W2894922801C535046627 @default.
• W2894922801 hasConceptScore W2894922801C71924100 @default.
• W2894922801 hasFunder F4320334661 @default.
• W2894922801 hasIssue "1" @default.
• W2894922801 hasLocation W28949228011 @default.
• W2894922801 hasLocation W28949228012 @default.
• W2894922801 hasLocation W28949228013 @default.
• W2894922801 hasLocation W28949228014 @default.
• W2894922801 hasLocation W28949228015 @default.
• W2894922801 hasLocation W28949228016 @default.
• W2894922801 hasOpenAccess W2894922801 @default.
• W2894922801 hasPrimaryLocation W28949228011 @default.
• W2894922801 hasRelatedWork W2003938723 @default.

• next